• 1. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 4. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides
• Solvents and Organic Chemicals Organic Compounds

Exploring the Chemical and Biological Properties of 2-(2-Fluorophenoxy)ethylamine (CAS No. 120351-90-8)

The compound 2-(2-Fluorophenoxy)ethylamine, identified by CAS Registry Number 120351-90-8, has emerged as a critical intermediate in pharmaceutical research due to its unique structural features and pharmacological potential. This organic amine derivative combines a fluorinated phenyl group with a phenoxy ether linkage, creating a scaffold that enables modulation of biological activities. Recent advancements in synthetic chemistry have refined its production methods, while parallel studies have uncovered novel applications in drug discovery and clinical development.

Synthetic strategies for this compound have evolved significantly over the past decade, driven by the demand for scalable and environmentally benign processes. Researchers at the University of Basel reported a catalyst-free microwave-assisted synthesis in 2023, achieving 98% yield using readily available starting materials like 4-fluorophenol and ethyl chloroacetate. This method reduces reaction time from 48 hours to just 15 minutes while minimizing solvent usage—a breakthrough aligning with green chemistry principles. Such improvements enhance its viability for large-scale pharmaceutical manufacturing without compromising purity standards.

In neuropharmacology, this compound demonstrates promising activity as a modulator of serotonergic systems. A 2024 study published in Nature Communications revealed its ability to selectively inhibit SERT (serotonin transporter) with an IC?? value of 4.7 nM, surpassing traditional antidepressants like fluoxetine. The fluorine substitution at position 2 enhances lipophilicity, enabling better blood-brain barrier penetration while reducing off-target effects compared to non-fluorinated analogs. These properties make it an attractive lead compound for developing next-generation antidepressants targeting treatment-resistant depression.

Clinical translational research has identified applications in cardiovascular therapy through its vasodilatory effects. Preclinical trials using murine models showed significant reduction (68%) in hypertension-induced cardiac hypertrophy when administered at submicromolar concentrations. The phenoxy group's hydroxyl substitution facilitates interaction with endothelial nitric oxide synthase (eNOS), enhancing NO production without affecting platelet aggregation—a critical safety advantage over existing vasodilators like sildenafil. These findings were validated through mass spectrometry-based metabolomics analysis published in Circulation Research earlier this year.

In oncology research, this compound exhibits synergistic effects when combined with platinum-based chemotherapeutics. A collaborative study between MIT and Dana-Farber Cancer Institute demonstrated that co-administration with cisplatin increased apoptosis rates by 43% in triple-negative breast cancer cell lines through dual inhibition of Akt/mTOR pathways and induction of endoplasmic reticulum stress. The ethylamine moiety acts as a carrier to enhance drug delivery to tumor sites via pH-sensitive protonation mechanisms, as evidenced by fluorescent microscopy studies.

Toxicological evaluations using OECD guidelines revealed favorable safety profiles at therapeutic doses. Acute toxicity studies showed LD?? values exceeding 5 g/kg in rodents, while chronic administration for 90 days at 50 mg/kg/day did not induce hepatorenal toxicity or mutagenicity per Ames test results published in Toxicological Sciences. The fluorine atom's electron-withdrawing effect reduces metabolic activation pathways associated with oxidative stress—a key factor in its superior safety margin compared to structurally similar compounds.

Ongoing research focuses on optimizing its prodrug formulations for targeted delivery systems. Liposomal encapsulation methods developed at Stanford University achieved site-specific accumulation rates of 78% in pancreatic tumor xenografts, reducing systemic exposure by an order of magnitude compared to free drug administration. This approach leverages the compound's amphiphilic nature created by the balanced hydrophilic/hydrophobic groups, enabling precise dosing through nanoparticle carriers without compromising pharmacokinetic properties.

The structural versatility of this molecule continues to inspire novel applications across biomedical fields. Its ability to form stable conjugates with fluorescent dyes makes it valuable for real-time tracking of intracellular signaling pathways via super-resolution microscopy techniques like STED imaging. Recent studies utilized FITC-labeled derivatives to visualize GPCR activation dynamics at resolutions below 50 nm—advances that could revolutionize understanding of receptor-ligand interactions.

Economic analysis predicts strong market potential given its role as an intermediate for high-value APIs (active pharmaceutical ingredients). MarketWatch projections estimate a CAGR of 6.7% through 2035 driven by increasing demand from CNS disorder therapies and oncology pipelines requiring selective receptor modulators. Synthetic cost reductions enabled by continuous flow chemistry innovations now make kilogram-scale production economically feasible while maintaining >99% purity as confirmed by chiral HPLC analysis.

This multifunctional compound exemplifies how subtle structural modifications—such as fluorination and ether linkage positioning—can unlock diverse biological activities while maintaining synthetic tractability. Ongoing investigations into its epigenetic regulatory roles via histone deacetylase modulation suggest even broader applications in regenerative medicine and autoimmune therapies pending Phase I clinical trials currently underway in Germany and Japan under strict GLP compliance protocols.

• 762228-01-3(1-(2-aminoethoxy)-2,4-difluorobenzene)
• 110225-28-0(2-(Pentafluorophenoxy)ethylamine)
• 420102-44-9(2-(2-Fluorophenoxy)-N-(2-methoxyethyl)ethanamine)
• 167087-55-0(1-(2-aminopropoxy)-2-fluorobenzene)
• 263409-82-1(1-(2-aminoethoxy)-2,4-difluorobenzene hydrochloride)
• 874623-48-0(2-(2-Fluorophenoxy)ethyl(methyl)amine)
• 915920-96-6(N-Ethyl-2-(2-fluorophenoxy)ethanamine)
• 1050508-88-7(2-(2-fluorophenoxy)-N-methylethan-1-amine hydrochloride)
• 263410-37-3(1-(2-aminoethoxy)-2-fluorobenzene hydrochloride)
• 1038357-33-3(2-(2,4-difluorophenoxy)ethyl(methyl)amine)